Documents

A list of downloadable documents created during development.

Assessment report sent for information

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: equality impact assessment - guidance development

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appraisal consultation

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin [ID342]: assessment report

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: scoping Equality Impact Assessment form

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final protocol

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final scope

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final matrix

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on draft scope

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on provisional matrix

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation October 2010

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix for consultation October 2010

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation (pre-referral)

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix (pre-referral)